Bio-Rad Laboratories (BIO) 10-Q 9 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 27, 2017
Entity Registrant Name	BIO RAD LABORATORIES INC
Entity Central Index Key	12,208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Common Class A [Member]
Entity Common Stock, Shares Outstanding		24,490,423
Common Class B [Member]
Entity Common Stock, Shares Outstanding		5,115,282

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
ASSETS:
Cash and cash equivalents	$ 291,663	$ 456,264
Short-term investments	382,412	383,176
Restricted investments	4,560	4,560
Accounts receivable, net	373,443	372,348
Inventories:
Raw materials	120,243	116,540
Work in process	126,620	125,982
Finished goods	312,956	282,439
Total inventories	559,819	524,961
Other current assets	120,674	103,215
Total current assets	1,732,571	1,844,524
Property, plant and equipment, at cost	1,261,505	1,227,388
Less: accumulated depreciation and amortization	(756,401)	(738,774)
Property, plant and equipment, net	505,104	488,614
Goodwill, net	516,191	477,115
Purchased intangibles, net	190,614	161,609
Other investments	955,620	830,790
Other assets	52,669	47,852
Total assets	3,952,769	3,850,504
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable, accrued payroll and employee benefits	231,485	296,473
Current maturities of long-term debt and notes payable	466	334
Income and other taxes payable	33,042	28,124
Other current liabilities	142,511	146,391
Total current liabilities	407,504	471,322
Long-term debt, net of current maturities	434,289	434,186
Other long-term liabilities	403,510	358,237
Total liabilities	1,245,303	1,263,745
Stockholders' equity:
Additional paid-in capital	342,584	332,911
Retained earnings	1,848,337	1,836,180
Accumulated other comprehensive income	516,643	417,766
Total stockholders' equity	2,707,466	2,586,759
Total liabilities and stockholders' equity	3,952,769	3,850,504
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class A [Member]
Stockholders' equity:
Treasury Stock, Value	(12)	(12)
Treasury Class B [Member]
Stockholders' equity:
Treasury Stock, Value	$ (89)	$ (89)

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets Parenthetical - shares	Mar. 31, 2017	Dec. 31, 2016
Common Class A [Member]
Common Stock, Shares, Issued	24,490,545	24,454,048
Common Stock, Shares, Outstanding	24,490,423	24,453,926
Common Class B [Member]
Common Stock, Shares, Issued	5,116,199	5,123,883
Common Stock, Shares, Outstanding	5,115,282	5,122,966
Treasury Class A [Member]
Treasury Stock, Shares	122	122
Treasury Class B [Member]
Treasury Stock, Shares	917	917

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net sales	$ 500,051	$ 471,197
Cost of goods sold	230,064	207,168
Gross profit	269,987	264,029
Selling, general and administrative expense	194,940	189,716
Research and Development Expense	49,488	48,586
Segment profit (loss)	25,559	25,727
Interest expense	5,041	5,580
Foreign exchange losses, net	1,789	1,129
Other (income) expense, net	(1,418)	(1,177)
Income before income taxes	20,147	20,195
Provision for income taxes	(7,734)	(7,919)
Net income including noncontrolling interests	12,413	12,276
Net income attributable to Bio-Rad	$ 12,413	$ 12,276
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 0.42	$ 0.42
Weighted average common shares - basic	29,580	29,364
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 0.41	$ 0.42
Weighted average common shares - diluted	29,911	29,506

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Net Income (Loss) Attributable to Parent	$ 12,413	$ 12,276
Foreign currency translation adjustments	18,843	37,935
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	(115)	(640)
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	80,149	(4,093)
Total other comprehensive income (loss) net of tax	98,877	33,202
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 111,290	$ 45,478

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Cash received from customers	$ 508,982	$ 492,407
Cash paid to suppliers and employees	(550,956)	(508,820)
Interest received (paid), net	329	187
Income tax (payments) refunds, net	(8,804)	10,421
Investment proceeds and miscellaneous receipts, net	1,658	1,667
Excess tax benefits from share-based compensation	0	(67)
(Payments for) proceeds from forward foreign exchange contracts, net	(7,429)	2,869
Net cash used in operating activities	(56,220)	(7,448)
Cash flows from investing activities:
Capital expenditures	(39,332)	(25,296)
Proceeds from dispositions of property, plant and equipment	15	1
Payments for acquisitions and long-term investments	(73,541)	(9,634)
Payments for purchases of marketable securities and investments	(68,305)	(71,485)
Proceeds from sales of marketable securities and investments	20,201	20,381
Proceeds from maturities of marketable securities and investments	50,570	35,175
Net cash used in investing activities	(110,392)	(50,858)
Cash flows from financing activities:
Net payments on line-of-credit arrangements and notes payable	(36)	0
Payments on long-term borrowings	(76)	(77)
Payments of contingent consideration	(3,105)	(3,500)
Proceeds from issuance of common stock for shared-based compensation	3,890	3,768
Excess tax benefits from share-based compensation	0	67
Net cash provided by financing activities	673	258
Effect of foreign exchange rate changes on cash	1,338	4,114
Net decrease in cash and cash equivalents	(164,601)	(53,934)
Cash and cash equivalents at beginning of period	456,264	457,549
Cash and cash equivalents at end of period	291,663	403,615
Adjustments to reconcile net income to net cash used in operating activities [Abstract]
Net income	12,413	12,276
Adjustments, Noncash Items, to Reconcile Net Income to Cash Used in Operating Activities [Abstract]
Depreciation and amortization	33,662	34,090
Share-based compensation	5,393	4,645
Gains on dispositions of securities	(126)	229
Excess tax benefits from share-based compensation	0	(67)
Changes in fair value of contingent consideration	(9,400)	(1,284)
Decrease in accounts receivable	6,846	19,991
Increase in inventories	(26,864)	(34,400)
Increase in other current assets	(19,155)	(15,730)
Decrease in accounts payable and other current liabilities	(61,155)	(47,666)
(Decrease) increase in income taxes payable	(1,655)	14,075
(Decrease) increase in Deferred Income Taxes	(163)	3,394
Net decrease/increase in other long-term assets/liabilities	3,984	2,999
Net cash used in operating activities	$ (56,220)	$ (7,448)

1. Organization, Consolidation

1. Organization, Consolidation and Presentation of Financial Statements	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	1. BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2016 . We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Recent Accounting Standards Updates In March 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation. In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017. In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 2 to the condensed consolidated financial statements). In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. As of March 31, 2017 and December 31, 2016, we had a limited amount of r e stricted cash of $2.0 million for both periods that were reported in either Prepaid expenses, Other current assets or Other assets in the Condensed Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar. In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers. Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements. ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which financial statements have not been issued or made available for issuance. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements. In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows. In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million , and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million , respectively, in the Condensed Consolidated Balance Sheet. In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.

2. Acquisitions

2. Acquisitions	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	ACQUISITIONS RainDance Technologies, Inc. In February 2017, we acquired all the issued and outstanding stock of RainDance Technologies, Inc. (RainDance) for approximately $75.2 million including certain assumed net liabilities. Cash payments at closing were $72.9 million . In addition, we had a cash payment of $10.0 million for a one-time expense associated with the acquisition that was recorded in Cost of goods sold. The acquisition was included in our Life Science segment’s results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The preliminary allocation of the payments were $10.0 million for the one-time expense, $35.0 million to purchased intangibles consisting primarily of a large patent and license portfolio, limited know how and customer relationships, $2.3 million to assumed net liabilities, and $34.8 million to goodwill. We recorded a deferred tax liability of $12.9 million related to the purchased intangibles and a deferred tax asset of $18.3 million related to the acquired net operating losses. The purchase price allocation is preliminary as additional time is required to complete the valuation of the intangibles. RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy. We believe that RainDance's droplet-based solutions will extend our reach into next-generation sequencing applications and strengthen our position in the area of Droplet Digital™ PCR, offering customers with solutions for a wide range of nucleic acid detection applications. Propel Labs, Inc. In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date. The fair value of the consideration as of the acquisition date was $32.8 million , which included $9.5 million paid in cash at the closing date and $23.3 million in contingent consideration potentially payable to Propel. The amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, and was recognized at its estimated fair value of $26.0 million as of March 31, 2017 (see Note 3, "Fair Value Measurements"). The fair values of the net assets acquired from Propel as of the acquisition date were determined to be $32.7 million of definite-lived intangible assets and $0.1 million of goodwill. The goodwill related to this acquisition will be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology.

3. Fair Value Measurements

3. Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2017 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 16.3 $ — $ 16.3 Foreign time deposits 10.2 — — 10.2 U.S. government sponsored agencies — 5.0 — 5.0 Money market funds 4.9 — — 4.9 Total cash equivalents (a) 15.1 21.3 — 36.4 Restricted investment: 4.6 — — 4.6 Available-for-sale investments: Corporate debt securities — 189.0 — 189.0 U.S. government sponsored agencies — 72.8 — 72.8 Foreign government obligations — 2.9 — 2.9 Brokered certificates of deposit — 3.6 — 3.6 Municipal obligations — 14.8 — 14.8 Marketable equity securities 894.1 — — 894.1 Asset-backed securities — 61.7 — 61.7 Total available-for-sale investments (b) 894.1 344.8 — 1,238.9 Forward foreign exchange contracts (c) — 3.1 — 3.1 Total financial assets carried at fair value $ 913.8 $ 369.2 $ — $ 1,283.0 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 1.7 $ — $ 1.7 Contingent consideration (e) — — 26.0 26.0 Total financial liabilities carried at fair value $ — $ 1.7 $ 26.0 $ 27.7 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 14.1 $ — $ 14.1 Foreign time deposits 11.8 — — 11.8 Domestic time deposits — 20.0 — 20.0 U.S. government sponsored agencies — 1.1 — 1.1 Money market funds 5.9 — — 5.9 Total cash equivalents (a) 17.7 35.2 — 52.9 Restricted investment: 4.6 — — 4.6 Available-for-sale investments: Corporate debt securities — 179.4 — 179.4 U.S. government sponsored agencies — 82.5 — 82.5 Foreign government obligations — 4.4 — 4.4 Brokered certificates of deposit — 3.6 — 3.6 Municipal obligations — 15.4 — 15.4 Marketable equity securities 767.8 — — 767.8 Asset-backed securities — 62.5 — 62.5 Total available-for-sale investments (b) 767.8 347.8 — 1,115.6 Forward foreign exchange contracts (c) — 0.6 — 0.6 Total financial assets carried at fair value $ 790.1 $ 383.6 $ — $ 1,173.7 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 1.3 $ — $ 1.3 Contingent consideration (e) — — 38.5 38.5 Total financial liabilities carried at fair value $ — $ 1.3 $ 38.5 $ 39.8 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, December 31, 2016 Short-term investments $ 382.4 $ 383.2 Other investments 856.5 732.4 Total $ 1,238.9 $ 1,115.6 (c) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (d) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (e) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2017 December 31, 2016 Other current liabilities $ 3.2 $ 14.5 Other long-term liabilities 22.8 24.0 Total $ 26.0 $ 38.5 In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a cell sorting system from Propel. Since 2012, we have paid $32.0 million upon reaching the milestones and have reduced the valuation of the milestones by $12.6 million . The remaining liability of $3.1 million was paid in February 2017 . During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020 . The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020 . The contingent consideration was recognized at its estimated fair value of $26.0 million as of March 31, 2017 . The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the three months ended March 31, 2017 (in millions): 2017 January 1 $ 28.5 Cell sorting system: Payment of sales milestone (3.1 ) Analytical flow cytometer platform: Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense 0.6 March 31 $ 26.0 The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of March 31, 2017 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11 % Cost of debt 4.6 % In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO, Inc. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The contingent consideration was revalued to a fair value of $10.0 million as of December 31, 2016 and was reversed to income during the first quarter of 2017 due to reaching a favorable outcome with GnuBIO, Inc. To estimate the fair value of Level 2 debt securities as of March 31, 2017 and December 31, 2016 , our primary pricing provider uses S&P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing. For commercial paper as of March 31, 2017 and December 31, 2016 , pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. Our pricing provider performs daily reasonableness testing of the S&P Capital IQ prices. Price changes of 5% or greater are investigated and resolved. In addition, we perform a quarterly testing of the S&P Capital IQ prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved. Available-for-sale investments consist of the following (in millions): March 31, 2017 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 189.0 $ 0.3 $ (0.3 ) $ 189.0 Brokered certificates of deposit 3.6 — — 3.6 Municipal obligations 14.9 — (0.1 ) 14.8 Asset-backed securities 61.4 0.2 (0.1 ) 61.5 U.S. government sponsored agencies 73.3 0.1 (0.6 ) 72.8 Foreign government obligations 2.9 — — 2.9 Marketable equity securities 32.4 5.7 (0.3 ) 37.8 377.5 6.3 (1.4 ) 382.4 Long-term investments: Marketable equity securities 54.5 801.8 — 856.3 Asset-backed securities 0.2 — — 0.2 54.7 801.8 — 856.5 Total $ 432.2 $ 808.1 $ (1.4 ) $ 1,238.9 December 31, 2016 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 179.7 $ 0.2 $ (0.5 ) $ 179.4 Brokered certificates of deposit 3.6 — — 3.6 Municipal obligations 15.5 — (0.1 ) 15.4 Asset-backed securities 62.2 0.1 (0.1 ) 62.2 U.S. government sponsored agencies 83.1 0.1 (0.7 ) 82.5 Foreign government obligations 4.4 — — 4.4 Marketable equity securities 32.4 3.7 (0.4 ) 35.7 380.9 4.1 (1.8 ) 383.2 Long-term investments: Marketable equity securities 54.5 677.6 — 732.1 Asset-backed securities 0.3 — — 0.3 54.8 677.6 — 732.4 Total $ 435.7 $ 681.7 $ (1.8 ) $ 1,115.6 The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares. The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, December 31, 2016 Fair value of investments in a loss position 12 months or more $ 8.9 $ 11.8 Fair value of investments in a loss position less than 12 months $ 158.4 $ 160.5 Gross unrealized losses for investments in a loss position 12 months or more $ 0.1 $ 0.3 Gross unrealized losses for investments in a loss position less than 12 months $ 1.3 $ 1.5 The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at March 31, 2017 or at December 31, 2016 . As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2017 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income. The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2017 Contracts maturing in April through June 2017 to sell foreign currency: Notional value $ 17.4 Unrealized gain $ 0.1 Contracts maturing in April through June 2017 to purchase foreign currency: Notional value $ 406.6 Unrealized gain $ 1.3 The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2017 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 151.7 $ 151.8 Mature in one to five years 139.6 139.4 Mature in more than five years 54.0 53.6 Total $ 345.3 $ 344.8 The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value. Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability. Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): March 31, 2017 December 31, 2016 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Other investments $ 93.4 $ 1,149.2 2 $ 92.8 $ 984.2 2 Total long-term debt, excluding leases and current maturities $ 422.6 $ 453.6 2 $ 422.5 $ 454.2 2 We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of March 31, 2017 . The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of January 1, 2017: Goodwill $ 207.1 $ 311.7 $ 518.8 Accumulated impairment losses (27.2 ) (14.5 ) (41.7 ) Goodwill, net 179.9 297.2 477.1 Acquisitions 34.8 — 34.8 Currency fluctuations 0.2 4.1 4.3 Balances as of March 31, 2017: Goodwill 242.1 315.8 557.9 Accumulated impairment losses (27.2 ) (14.5 ) (41.7 ) Goodwill, net $ 214.9 $ 301.3 $ 516.2 In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded $0.1 million of goodwill and $32.7 million of definite-lived intangible assets: $29.7 million of developed product technology and $3.0 million of covenants not to compete. In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions), we recorded $34.8 million of goodwill and $35.0 million for licenses. Other than goodwill, we have no intangible assets with indefinite lives. Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions): March 31, 2017 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-8 $ 85.7 $ (55.1 ) $ 30.6 Know how 1-9 184.0 (140.6 ) 43.4 Developed product technology 2-12 126.7 (58.9 ) 67.8 Licenses 1-14 74.1 (31.4 ) 42.7 Tradenames 4-8 3.6 (2.7 ) 0.9 Covenants not to compete 2-7 7.8 (2.6 ) 5.2 Total definite-lived intangible assets $ 481.9 $ (291.3 ) $ 190.6 December 31, 2016 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-8 $ 84.4 $ (52.8 ) $ 31.6 Know how 1-9 182.6 (136.9 ) 45.7 Developed product technology 3-12 125.9 (56.3 ) 69.6 Licenses 1-9 39.0 (30.6 ) 8.4 Tradenames 4-8 3.5 (2.5 ) 1.0 Covenants not to compete 2-9 7.8 (2.5 ) 5.3 Total definite-lived intangible assets $ 443.2 $ (281.6 ) $ 161.6 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2017 2016 Amortization expense $ 6.9 $ 9.4

5. Product Warranty Liability

5. Product Warranty Liability	3 Months Ended
	Mar. 31, 2017
Product Warranties Disclosures [Abstract]
Product Warranty Liability	5. PRODUCT WARRANTY LIABILITY We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2017 $ 17.6 Provision for warranty 8.0 Actual warranty costs (8.0 ) March 31, 2017 $ 17.6

6. Long-Term Debt

6. Long-Term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt	6. LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): March 31, December 31, 2016 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (2.4 ) (2.5 ) Long-term debt less unamortized discount and debt issuance costs 422.6 422.5 Capital leases and other debt 12.2 12.0 434.8 434.5 Less current maturities (0.5 ) (0.3 ) Long-term debt $ 434.3 $ 434.2 Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 ( 4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946% . The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of March 31, 2017 or December 31, 2016 , however $0.8 million was utilized for domestic standby letters of credit that reduced our borrowing availability. The Credit Agreement matures in June 2019 . If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.40% at March 31, 2017 . The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of March 31, 2017

7. Accumulated Other Comprehen

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	7. ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2017: $ 1.3 $ (18.6 ) $ 435.0 $ 417.7 Other comprehensive income (loss), before reclassifications 18.8 (0.3 ) 127.1 145.6 Amounts reclassified from Accumulated other comprehensive income — 0.2 (0.2 ) — Income tax effects — — (46.7 ) (46.7 ) Other comprehensive income (loss), net of income taxes 18.8 (0.1 ) 80.2 98.9 Balances as of March 31, 2017: $ 20.1 $ (18.7 ) $ 515.2 $ 516.6 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding losses on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2016: $ 33.7 $ (20.7 ) $ 369.1 $ 382.1 Other comprehensive income (loss), before reclassifications 37.9 (0.9 ) (6.5 ) 30.5 Amounts reclassified from Accumulated other comprehensive income — 0.3 — 0.3 Income tax effects — — 2.4 2.4 Other comprehensive income (loss), net of income taxes 37.9 (0.6 ) (4.1 ) 33.2 Balances as of March 31, 2016: $ 71.6 $ (21.3 ) $ 365.0 $ 415.3 The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended March 31, Components of Comprehensive income 2017 2016 Location Amortization of foreign other post-employment benefit items $ (0.2 ) $ (0.3 ) Selling, general and administrative expense Net holding gains on available-for-sale investments $ 0.2 $ — Other (income) expense, net

8. Earnings Per Share

8. Earnings Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	8. EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2017 2016 Basic weighted average shares outstanding 29,580 29,364 Effect of potentially dilutive stock options and restricted stock awards 331 142 Diluted weighted average common shares 29,911 29,506 Anti-dilutive shares 17 90

9. Other Income and Expenses

9. Other Income and Expenses	3 Months Ended
	Mar. 31, 2017
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	9. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2017 2016 Interest and investment income $ (1.1 ) $ (1.2 ) Net realized gain on investments (0.3 ) — Other (income) expense, net $ (1.4 ) $ (1.2 )

10. Income Taxes

10. Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES Our effective income tax rate was 38% and 39% for the three months ended March 31, 2017 and 2016 , respectively. The effective tax rate for the first quarter of 2017 and 2016 was higher than the U.S. federal statutory tax rate primarily due to losses incurred in certain foreign jurisdictions for which no income tax benefit is expected. Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate including Switzerland and Singapore have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35% . Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and tax credits. Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. As of March 31, 2017 , based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $3.5 million

11. Segment Information

11. Segment Information	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION Information regarding industry segments for the three months ended March 31, 2017 and 2016 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2017 $ 174.3 $ 322.3 $ 3.5 2016 $ 165.9 $ 301.7 $ 3.6 Segment net (loss) profit 2017 $ (18.8 ) $ 41.0 $ 0.2 2016 $ (3.3 ) $ 24.8 $ 0.3 Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. See Note 13 for a discussion of restructuring costs. The following reconciles total segment profit to consolidated income before taxes (in millions): Three Months Ended March 31, 2017 2016 Total segment profit $ 22.4 $ 21.8 Foreign currency exchange losses, net (1.8 ) (1.1 ) Net corporate operating, interest and other expense not allocated to segments (1.9 ) (1.7 ) Other income (expense), net 1.4 1.2 Consolidated income before income taxes $ 20.1 $ 20.2

12. Legal Proceedings

12. Legal Proceedings	3 Months Ended
	Mar. 31, 2017
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	12. LEGAL PROCEEDINGS On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our then current directors and one former director. We were also named as a nominal defendant. In the complaint, the plaintiff alleged that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors had been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff sought an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors ("Board") via its counsel in this action. The letter demanded that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it was not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case was stayed pending mediation. The caption was City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. The lawsuit and demand letter are referred to collectively as the “California Action”. On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our then current directors and one former director. We were named as a nominal defendant in the complaints. The complaints alleged that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs asserted claims for breach of fiduciary duty and unjust enrichment and requested an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015. The case was stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). The cases filed in the Delaware Court of Chancery, together with the California Action, are referred to collectively as the “Derivative Actions”. The parties filed a Stipulation dated November 4, 2016 with the Superior Court of California for Contra Costa County that set forth the terms of a proposed settlement of the Derivative Actions. The proposed settlement included the dismissal with prejudice of all claims asserted in the Derivative Actions, an agreed-upon set of revised corporate procedures, and no monetary payment other than an award of attorneys’ fees and costs to the plaintiffs’ counsel. We and the other defendants did not admit any liability or fault in connection with the proposed settlement. On December 22, 2016 the Superior Court of California for Contra Costa County issued an order granting preliminary approval of this proposed settlement. The Court held a hearing for final approval of the settlement on March 2, 2017, and the Court approved the settlement. On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The parties engaged in mediation of the case on April 19, 2016 and on September 14, 2016. The mediations did not result in a settlement. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million , plus prejudgment interest of $141,608 , post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We have provided for the judgment, interest and Mr. Wadler's litigation costs. In March 2017 we filed with the court a Notice of Motion and Renewed Motion for Judgment as a Matter of Law and Motion for a New Trial. Bio-Rad received three notices of violations from the Bay Area Air Quality Management District (“District”). The District alleges that we operated three (3) power generation units without appropriate monitoring and recordkeeping and exceeded permissible levels of emissions during those operations. We are cooperating with the District and are investigating the allegations. No formal proceeding has been initiated by the District.

13. Restructuring Costs (Notes)

13. Restructuring Costs (Notes)	3 Months Ended
	Mar. 31, 2017
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	13. RESTRUCTURING COSTS For the three months ended March 31, 2017 , we recorded less than $0.1 million related to restructuring actions that include the elimination or relocation of various positions. These actions are generally intended to streamline and focus our efforts and more properly align our cost structure with projected future revenue streams. The following table summarizes the activity of our restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balance at December 31, 2016 $ 3.2 $ 5.8 $ 9.0 Charged to expense — — — Adjustment to expense — — — Cash payments (0.3 ) (0.6 ) (0.9 ) Foreign currency translation losses — 0.1 0.1 Balance at March 31, 2017 $ 2.9 $ 5.3 $ 8.2 In May, 2016, management announced that it will take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and other employee benefits for the three months ended March 31, 2017 . The liability of $8.2 million as of March 31, 2017 encompassed a short-term liability of $5.8 million and a long-term liability of $2.4 million , and is anticipated to be paid through 2019. The amounts recorded were reflected in Cost of goods sold of $(0.1) million and in Selling, general and administrative expense of $0.1 million in the Condensed Consolidated Statements of Income for the three months ended March 31, 2017

1. Basis of Presentation and U

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	In March 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." ASU 2017-07 will change how employers that sponsor defined benefit pension and/or other postretirement benefit plans present the net periodic benefit cost, which is comprised of several components, in the income statement. Under ASU 2017-07, employers will present the service cost component of the net periodic benefit cost in the same income statement line item(s) as other employee compensation costs arising from services rendered during the period, and will be the only costs eligible for capitalization. Employers will present the other components separately from the line item(s) that includes the service cost outside of the subtotal of Income from operations. ASU 2017-07 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Employers will apply the guidance on the presentation of the components of net periodic benefit cost in the income statement retrospectively. In several foreign locations, we are statutorily required to provide a lump sum severance or termination indemnity to our employees and are currently evaluating the applicability of ASU 2017-07 to our situation. In January 2017, the FASB issued ASU 2017-04, "Simplifying the Test for Goodwill Impairment." ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. ASU 2017-04 is effective prospectively for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for any impairment tests performed after January 1, 2017. ASU 2017-04 will provide a more stream-lined approach to evaluating future goodwill impairment and we early adopted on January 1, 2017 on a prospective basis as a change in accounting principle. There was no impact of ASU 2017-04 on our consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017. In January 2017, the FASB issued ASU 2017-01, "Clarifying the Definition of a Business." ASU 2017-01 changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. If substantially all of the fair value is concentrated in a single asset or a group of similar assets, the acquired set is not a business. If this is not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. Determining whether a set constitutes a business is critical because the accounting for a business combination differs significantly from that of an asset acquisition. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. ASU 2017-01 will be applied prospectively to any transactions occurring within the period of adoption. Early adoption is permitted, including for interim or annual periods in which the financial statements have not been issued or made available for issuance. We early adopted ASU 2017-01 on January 1, 2017 on a prospective basis. For our acquisition of RainDance Technologies, Inc., ASU 2017-01 did not affect the conclusion of it being a business combination (see Note 2 to the condensed consolidated financial statements). In November 2016, the FASB issued ASU 2016-18, "Restricted Cash." ASU 2016-18 requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. ASU 2016-18 will be applied retrospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. Early adoption is permitted. As of March 31, 2017 and December 31, 2016, we had a limited amount of r e stricted cash of $2.0 million for both periods that were reported in either Prepaid expenses, Other current assets or Other assets in the Condensed Consolidated Balance Sheets. At the time of adoption, we cannot assure whether these same restricted cash amounts will be held or what other restricted cash we may have, or that historically reported amounts will be similar. In October 2016, the FASB issued ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory." ASU 2016-16 requires immediate recognition of income tax consequences of intercompany asset transfers, other than inventory transfers. Existing GAAP prohibits recognition of income tax consequences of intercompany asset transfers whereby the seller defers any net tax effect and the buyer is prohibited from recognizing a deferred tax asset on the difference between the newly created tax basis of the asset in its tax jurisdiction and its financial statement carrying amount as reported in the consolidated financial statements. ASU 2016-16 specifically excludes from its scope intercompany inventory transfers whereby the recognition of tax consequences will take place when the inventory is sold to third parties. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as of the beginning of an annual reporting period for which financial statements have not been issued or made available for issuance. We are currently evaluating the effect ASU 2016-16 will have on our consolidated financial statements. In August 2016, FASB issued ASU 2016-15, "Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the effect ASU 2016-15 will have on our consolidated statements of cash flows. In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted for all entities for annual periods beginning after December 15, 2018, and interim periods therein. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. We adopted ASU 2016-09 prospectively as a change in accounting principal on January 1, 2017, and made a policy election to account for forfeitures as they occur. As a result of adopting ASU 2016-09 as of January 1, 2017, the cumulative effect of the change on Retained earnings decreased by $0.3 million , and increased Additional paid-in capital and Deferred tax assets by $0.4 million and $0.1 million , respectively, in the Condensed Consolidated Balance Sheet. In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that does not consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. We adopted ASU 2016-07 on January 1, 2017 on a prospective basis, which currently has not affected our condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently gathering, documenting and analyzing lease agreements related to this ASU and anticipate material additions to the balance sheet for right-of-use assets, offset by the associated liabilities. In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For equity securities that would be affected by ASU 2016-01, see the available-for-sale investments table in Note 3 to the condensed consolidated financial statements. At the time of adoption, we cannot assure whether these same equity securities will be held or what other equity securities we may have. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” We prospectively adopted ASU 2015-11 as a change in accounting principle on January 1, 2017, which did not have a material impact on our condensed consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In December 2016, the FASB issued ASU 2016-20, "Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers" which affect narrow aspects of the guidance issued in ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients," which amends and clarifies certain aspects in ASU 2014-09 that include collectiblity, presentation of sales and other taxes collected from customers, noncash consideration, contract modifications and completed contracts at transition. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, the FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-20, 2016-12, 2016-10 and 2016-08 on January 1, 2018. We have completed revenue recognition diagnostic surveys across all regions in our decentralized sales contracting process, which is based on local country commercial regulations and practices. We are in the process of assessing individual contracts to identify performance obligations under these ASU’s, as compared with the deliverables and separate units of accounting previously identified under current U.S. GAAP, to determine the effect that these ASU’s will have on our consolidated financial statements and related disclosures.

3. Fair Value Measurements (Ta

3. Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities carried at fair value on a recurring basis	Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2017 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 16.3 $ — $ 16.3 Foreign time deposits 10.2 — — 10.2 U.S. government sponsored agencies — 5.0 — 5.0 Money market funds 4.9 — — 4.9 Total cash equivalents (a) 15.1 21.3 — 36.4 Restricted investment: 4.6 — — 4.6 Available-for-sale investments: Corporate debt securities — 189.0 — 189.0 U.S. government sponsored agencies — 72.8 — 72.8 Foreign government obligations — 2.9 — 2.9 Brokered certificates of deposit — 3.6 — 3.6 Municipal obligations — 14.8 — 14.8 Marketable equity securities 894.1 — — 894.1 Asset-backed securities — 61.7 — 61.7 Total available-for-sale investments (b) 894.1 344.8 — 1,238.9 Forward foreign exchange contracts (c) — 3.1 — 3.1 Total financial assets carried at fair value $ 913.8 $ 369.2 $ — $ 1,283.0 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 1.7 $ — $ 1.7 Contingent consideration (e) — — 26.0 26.0 Total financial liabilities carried at fair value $ — $ 1.7 $ 26.0 $ 27.7 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2016 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 14.1 $ — $ 14.1 Foreign time deposits 11.8 — — 11.8 Domestic time deposits — 20.0 — 20.0 U.S. government sponsored agencies — 1.1 — 1.1 Money market funds 5.9 — — 5.9 Total cash equivalents (a) 17.7 35.2 — 52.9 Restricted investment: 4.6 — — 4.6 Available-for-sale investments: Corporate debt securities — 179.4 — 179.4 U.S. government sponsored agencies — 82.5 — 82.5 Foreign government obligations — 4.4 — 4.4 Brokered certificates of deposit — 3.6 — 3.6 Municipal obligations — 15.4 — 15.4 Marketable equity securities 767.8 — — 767.8 Asset-backed securities — 62.5 — 62.5 Total available-for-sale investments (b) 767.8 347.8 — 1,115.6 Forward foreign exchange contracts (c) — 0.6 — 0.6 Total financial assets carried at fair value $ 790.1 $ 383.6 $ — $ 1,173.7 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 1.3 $ — $ 1.3 Contingent consideration (e) — — 38.5 38.5 Total financial liabilities carried at fair value $ — $ 1.3 $ 38.5 $ 39.8 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, December 31, 2016 Short-term investments $ 382.4 $ 383.2 Other investments 856.5 732.4 Total $ 1,238.9 $ 1,115.6 (c) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (d) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (e) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2017 December 31, 2016 Other current liabilities $ 3.2 $ 14.5 Other long-term liabilities 22.8 24.0 Total $ 26.0 $ 38.5
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the three months ended March 31, 2017 (in millions): 2017 January 1 $ 28.5 Cell sorting system: Payment of sales milestone (3.1 ) Analytical flow cytometer platform: Increase in estimated fair value of contingent consideration included in Selling, general and administrative expense 0.6 March 31 $ 26.0
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of March 31, 2017 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Valuation Technique Unobservable Input Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Discount rate 11 % Cost of debt 4.6 %
Schedule of available-for-sale investments	Available-for-sale investments consist of the following (in millions): March 31, 2017 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 189.0 $ 0.3 $ (0.3 ) $ 189.0 Brokered certificates of deposit 3.6 — — 3.6 Municipal obligations 14.9 — (0.1 ) 14.8 Asset-backed securities 61.4 0.2 (0.1 ) 61.5 U.S. government sponsored agencies 73.3 0.1 (0.6 ) 72.8 Foreign government obligations 2.9 — — 2.9 Marketable equity securities 32.4 5.7 (0.3 ) 37.8 377.5 6.3 (1.4 ) 382.4 Long-term investments: Marketable equity securities 54.5 801.8 — 856.3 Asset-backed securities 0.2 — — 0.2 54.7 801.8 — 856.5 Total $ 432.2 $ 808.1 $ (1.4 ) $ 1,238.9 December 31, 2016 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 179.7 $ 0.2 $ (0.5 ) $ 179.4 Brokered certificates of deposit 3.6 — — 3.6 Municipal obligations 15.5 — (0.1 ) 15.4 Asset-backed securities 62.2 0.1 (0.1 ) 62.2 U.S. government sponsored agencies 83.1 0.1 (0.7 ) 82.5 Foreign government obligations 4.4 — — 4.4 Marketable equity securities 32.4 3.7 (0.4 ) 35.7 380.9 4.1 (1.8 ) 383.2 Long-term investments: Marketable equity securities 54.5 677.6 — 732.1 Asset-backed securities 0.3 — — 0.3 54.8 677.6 — 732.4 Total $ 435.7 $ 681.7 $ (1.8 ) $ 1,115.6
Summary of fair value of gross unrealized losses for investments with unrealized losses	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, December 31, 2016 Fair value of investments in a loss position 12 months or more $ 8.9 $ 11.8 Fair value of investments in a loss position less than 12 months $ 158.4 $ 160.5 Gross unrealized losses for investments in a loss position 12 months or more $ 0.1 $ 0.3 Gross unrealized losses for investments in a loss position less than 12 months $ 1.3 $ 1.5
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2017 Contracts maturing in April through June 2017 to sell foreign currency: Notional value $ 17.4 Unrealized gain $ 0.1 Contracts maturing in April through June 2017 to purchase foreign currency: Notional value $ 406.6 Unrealized gain $ 1.3
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2017 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 151.7 $ 151.8 Mature in one to five years 139.6 139.4 Mature in more than five years 54.0 53.6 Total $ 345.3 $ 344.8
Estimated fair value of financial instruments	The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): March 31, 2017 December 31, 2016 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Other investments $ 93.4 $ 1,149.2 2 $ 92.8 $ 984.2 2 Total long-term debt, excluding leases and current maturities $ 422.6 $ 453.6 2 $ 422.5 $ 454.2 2

4. Intangible Assets, Goodwi22

4. Intangible Assets, Goodwill and Other (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of January 1, 2017: Goodwill $ 207.1 $ 311.7 $ 518.8 Accumulated impairment losses (27.2 ) (14.5 ) (41.7 ) Goodwill, net 179.9 297.2 477.1 Acquisitions 34.8 — 34.8 Currency fluctuations 0.2 4.1 4.3 Balances as of March 31, 2017: Goodwill 242.1 315.8 557.9 Accumulated impairment losses (27.2 ) (14.5 ) (41.7 ) Goodwill, net $ 214.9 $ 301.3 $ 516.2 In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded $0.1 million of goodwill and $32.7 million of definite-lived intangible assets: $29.7 million of developed product technology and $3.0 million of covenants not to compete. In conjunction with the purchase of all the issued and outstanding stock of RainDance Technologies, Inc. in February 2017 (see Note 2, "Acquisitions), we recorded $34.8 million of goodwill and $35.0 million
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with definite lives is as follows (in millions): March 31, 2017 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-8 $ 85.7 $ (55.1 ) $ 30.6 Know how 1-9 184.0 (140.6 ) 43.4 Developed product technology 2-12 126.7 (58.9 ) 67.8 Licenses 1-14 74.1 (31.4 ) 42.7 Tradenames 4-8 3.6 (2.7 ) 0.9 Covenants not to compete 2-7 7.8 (2.6 ) 5.2 Total definite-lived intangible assets $ 481.9 $ (291.3 ) $ 190.6 December 31, 2016 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 1-8 $ 84.4 $ (52.8 ) $ 31.6 Know how 1-9 182.6 (136.9 ) 45.7 Developed product technology 3-12 125.9 (56.3 ) 69.6 Licenses 1-9 39.0 (30.6 ) 8.4 Tradenames 4-8 3.5 (2.5 ) 1.0 Covenants not to compete 2-9 7.8 (2.5 ) 5.3 Total definite-lived intangible assets $ 443.2 $ (281.6 ) $ 161.6
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2017 2016 Amortization expense $ 6.9 $ 9.4

5. Product Warranty Liability

5. Product Warranty Liability (Tables)	3 Months Ended
	Mar. 31, 2017
Product Warranties Disclosures [Abstract]
Components of warranty accrual	Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2017 $ 17.6 Provision for warranty 8.0 Actual warranty costs (8.0 ) March 31, 2017 $ 17.6

6. Long-Term Debt (Tables)

6. Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): March 31, December 31, 2016 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (2.4 ) (2.5 ) Long-term debt less unamortized discount and debt issuance costs 422.6 422.5 Capital leases and other debt 12.2 12.0 434.8 434.5 Less current maturities (0.5 ) (0.3 ) Long-term debt $ 434.3 $ 434.2

7. Accumulated Other Compreh25

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2017: $ 1.3 $ (18.6 ) $ 435.0 $ 417.7 Other comprehensive income (loss), before reclassifications 18.8 (0.3 ) 127.1 145.6 Amounts reclassified from Accumulated other comprehensive income — 0.2 (0.2 ) — Income tax effects — — (46.7 ) (46.7 ) Other comprehensive income (loss), net of income taxes 18.8 (0.1 ) 80.2 98.9 Balances as of March 31, 2017: $ 20.1 $ (18.7 ) $ 515.2 $ 516.6 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding losses on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2016: $ 33.7 $ (20.7 ) $ 369.1 $ 382.1 Other comprehensive income (loss), before reclassifications 37.9 (0.9 ) (6.5 ) 30.5 Amounts reclassified from Accumulated other comprehensive income — 0.3 — 0.3 Income tax effects — — 2.4 2.4 Other comprehensive income (loss), net of income taxes 37.9 (0.6 ) (4.1 ) 33.2 Balances as of March 31, 2016: $ 71.6 $ (21.3 ) $ 365.0 $ 415.3
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]	The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended March 31, Components of Comprehensive income 2017 2016 Location Amortization of foreign other post-employment benefit items $ (0.2 ) $ (0.3 ) Selling, general and administrative expense Net holding gains on available-for-sale investments $ 0.2 $ — Other (income) expense, net

8. Earnings Per Share (Tables)

8. Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2017 2016 Basic weighted average shares outstanding 29,580 29,364 Effect of potentially dilutive stock options and restricted stock awards 331 142 Diluted weighted average common shares 29,911 29,506 Anti-dilutive shares 17 90

9. Other Income and Expenses (

9. Other Income and Expenses (Tables)	3 Months Ended
	Mar. 31, 2017
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2017 2016 Interest and investment income $ (1.1 ) $ (1.2 ) Net realized gain on investments (0.3 ) — Other (income) expense, net $ (1.4 ) $ (1.2 )

11. Segment Information (Table

11. Segment Information (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Information regarding industry segments	Information regarding industry segments for the three months ended March 31, 2017 and 2016 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2017 $ 174.3 $ 322.3 $ 3.5 2016 $ 165.9 $ 301.7 $ 3.6 Segment net (loss) profit 2017 $ (18.8 ) $ 41.0 $ 0.2 2016 $ (3.3 ) $ 24.8 $ 0.3
Reconciliation of segment profit to consolidated income before taxes	The following reconciles total segment profit to consolidated income before taxes (in millions): Three Months Ended March 31, 2017 2016 Total segment profit $ 22.4 $ 21.8 Foreign currency exchange losses, net (1.8 ) (1.1 ) Net corporate operating, interest and other expense not allocated to segments (1.9 ) (1.7 ) Other income (expense), net 1.4 1.2 Consolidated income before income taxes $ 20.1 $ 20.2

13. Restructuring Costs (Tables

13. Restructuring Costs (Tables)	3 Months Ended
	Mar. 31, 2017
Restructuring Costs [Abstract]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity of our restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balance at December 31, 2016 $ 3.2 $ 5.8 $ 9.0 Charged to expense — — — Adjustment to expense — — — Cash payments (0.3 ) (0.6 ) (0.9 ) Foreign currency translation losses — 0.1 0.1 Balance at March 31, 2017 $ 2.9 $ 5.3 $ 8.2

1. Basis of Presentation and30

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Jan. 01, 2017	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted Cash and Cash Equivalents, Current	$ 2,000		$ 2,000
Retained earnings	1,848,337		1,836,180
Additional paid-in-capital	$ 342,584		$ 332,911
Adjustments for New Accounting Pronouncement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings		$ (300)
Additional paid-in-capital		400
Deferred Tax Assets, Gross		$ 100

2. Acquisitions (Details)

2. Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Feb. 15, 2017	Dec. 31, 2016	Jan. 06, 2016	Apr. 10, 2014
Business Acquisition [Line Items]
Goodwill	$ 516,191			$ 477,115
Goodwill, Acquired During Period	34,800
RainDance Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	75,200
Payments to Acquire Businesses, Net of Cash Acquired	72,900
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed	10,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 35,000
Goodwill, Acquired During Period	34,800
Liabilities Assumed	12,900
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			(2,300)
Analytical Flow Cytometer Platform [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred		$ 32,800
Payments to Acquire Businesses, Net of Cash Acquired		9,500
Business Combination, Contingent Consideration, Liability	$ 26,000				$ 23,300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 32,700
Goodwill, Acquired During Period		$ 100
GnuBIO [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability				$ 10,000		$ 10,700
Deferred Tax Asset [Domain] | RainDance Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 18,300

3. Fair Value Measurements Fai

3. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		Mar. 31, 2017	Dec. 31, 2016	Jan. 06, 2016
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		$ 4.6	$ 4.6
Available-for-sale Securities, Fair Value Disclosure	[1]	1,238.9	1,115.6
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	3.1	0.6
Assets, Fair Value Disclosure		1,283	1,173.7
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	1.7	1.3
Business Combination, Contingent Consideration, Liability	[4]	26	38.5
Liabilities, Fair Value Disclosure		27.7	39.8
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		4.6	4.6
Available-for-sale Securities, Fair Value Disclosure	[1]	894.1	767.8
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0	0
Assets, Fair Value Disclosure		913.8	790.1
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	0	0
Business Combination, Contingent Consideration, Liability	[4]	0	0
Liabilities, Fair Value Disclosure		0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Available-for-sale Securities, Fair Value Disclosure	[1]	344.8	347.8
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	3.1	0.6
Assets, Fair Value Disclosure		369.2	383.6
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	1.7	1.3
Business Combination, Contingent Consideration, Liability	[4]	0	0
Liabilities, Fair Value Disclosure		1.7	1.3
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0	0
Assets, Fair Value Disclosure		0	0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	0	0
Business Combination, Contingent Consideration, Liability	[4]	26	38.5
Liabilities, Fair Value Disclosure		26	38.5
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	5	1.1
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	5	1.1
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	16.3	14.1
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	16.3	14.1
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	10.2	11.8
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	10.2	11.8
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		20
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		0
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		20
Domestic time deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]		0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	4.9	5.9
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	4.9	5.9
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	36.4	52.9
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	15.1	17.7
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	21.3	35.2
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0	0
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	3.6	3.6
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	3.6	3.6
Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	894.1	767.8
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	894.1	767.8
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	14.8	15.4
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	14.8	15.4
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	2.9	4.4
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	2.9	4.4
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	189	179.4
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	189	179.4
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	72.8	82.5
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	72.8	82.5
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	61.7	62.5
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	61.7	62.5
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0	0
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		3.2	14.5
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		22.8	24
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		382.4	383.2
Short-term Investments [Member] | Brokered certificates of deposit [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		3.6	3.6
Short-term Investments [Member] | Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		37.8	35.7
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		14.8	15.4
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		2.9	4.4
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		189	179.4
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		72.8	82.5
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		61.5	62.2
Other Investments [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		856.5	$ 732.4
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		26		$ 23.3
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, December 31, 2016 Short-term investments $ 382.4 $ 383.2 Other investments 856.5 732.4 Total $ 1,238.9 $ 1,115.6
[2]	Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.
[3]	Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.
[4]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2017 December 31, 2016 Other current liabilities $ 3.2 $ 14.5 Other long-term liabilities 22.8 24.0 Total $ 26.0 $ 38.5
[5]	Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

3. Fair Value Measurements 3.

3. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended	48 Months Ended
		Mar. 31, 2017	Sep. 30, 2016	Dec. 31, 2016	Jan. 06, 2016	Apr. 10, 2014	Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value		$ 26		$ 28.5
CellSorter [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(3.1)	$ (32)
(Decrease) increase in fair value of contingent consideration included in SGA			$ (12.6)
Business Combination, Contingent Consideration, Liability				3.1			$ 44.6
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		26			$ 23.3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances		$ 0.6
GnuBIO [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability				10		$ 10.7
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Inputs, Entity Credit Risk		11.00%
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Inputs, Entity Credit Risk		4.60%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	26		38.5
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		22.8		24
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		$ 3.2		$ 14.5
[1]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2017 December 31, 2016 Other current liabilities $ 3.2 $ 14.5 Other long-term liabilities 22.8 24.0 Total $ 26.0 $ 38.5

3. Foreign Exchange Forward Co

3. Foreign Exchange Forward Contracts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Notional value	$ 17.4
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	0.1
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Notional value	406.6
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ 1.3

3. Available-for-Sale Investme

3. Available-for-Sale Investments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions		Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 432.2	$ 435.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		808.1	681.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1.4)	(1.8)
Estimated Fair Value	[1]	1,238.9	1,115.6
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	189	179.4
Brokered certificates of deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	3.6	3.6
Municipal obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	14.8	15.4
Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	61.7	62.5
Marketable Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	894.1	767.8
US Government Sponsored Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	72.8	82.5
Foreign Government Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	2.9	4.4
Other Long-term Investments [Member] | Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		0.2	0.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		0.2	0.3
Other Long-term Investments [Member] | Marketable Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		54.5	54.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		801.8	677.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		856.3	732.1
Other Long-term Investments [Member] | Available-for-sale Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		54.7	54.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		801.8	677.6
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		856.5	732.4
Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value		382.4	383.2
Short-term Investments [Member] | Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		189	179.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.3	0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.3)	(0.5)
Estimated Fair Value		189	179.4
Short-term Investments [Member] | Brokered certificates of deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		3.6	3.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		3.6	3.6
Short-term Investments [Member] | Municipal obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		14.9	15.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)	(0.1)
Estimated Fair Value		14.8	15.4
Short-term Investments [Member] | Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		61.4	62.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.2	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)	(0.1)
Estimated Fair Value		61.5	62.2
Short-term Investments [Member] | Marketable Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		32.4	32.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		5.7	3.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.3)	(0.4)
Estimated Fair Value		37.8	35.7
Short-term Investments [Member] | Available-for-sale Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		377.5	380.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		6.3	4.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1.4)	(1.8)
Estimated Fair Value		382.4	383.2
Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		73.3	83.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.6)	(0.7)
Estimated Fair Value		72.8	82.5
Short-term Investments [Member] | Foreign Government Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		2.9	4.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		$ 2.9	$ 4.4
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, December 31, 2016 Short-term investments $ 382.4 $ 383.2 Other investments 856.5 732.4 Total $ 1,238.9 $ 1,115.6

3. Amortized Cost and Fair Val

3. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Mar. 31, 2017USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 151.7
Mature in one to five years	139.6
Mature in more than five years	54
Total Amortized Cost	345.3
Mature in less than one year	151.8
Mature in one to five years	139.4
Mature in more than five years	53.6
Estimated Fair Value	$ 344.8

3. Fair Value and Gross Unreal

3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Price Change Debt Security	5.00%
Tolerable variance Level 2 debt security pricing	1.00%
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more	$ 8.9	$ 11.8
Cost Method Investment, Percentage Owned	35.00%
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months	$ 158.4	160.5
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0.1	0.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 1.3	$ 1.5

3. Fair Value Financial Instru

3. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Investments	$ 93.4	$ 92.8
Total long-term debt, excluding capital leases and current maturities	422.6	422.5
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Investments	1,149.2	984.2
Total long-term debt, excluding capital leases and current maturities	$ 453.6	$ 454.2

4. Intangible Assets, Goodwi39

4. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill	$ 557,900	$ 518,800
Accumulated impairment loss	(41,700)	(41,700)
Goodwill, net	516,191	477,115
Goodwill, Acquired During Period	34,800
Currency fluctuations	4,300
Life Science [Member]
Goodwill [Line Items]
Goodwill	242,100	207,100
Accumulated impairment loss	(27,200)	(27,200)
Goodwill, net	214,900	179,900
Goodwill, Acquired During Period	34,800
Currency fluctuations	200
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill	315,800	311,700
Accumulated impairment loss	(14,500)	(14,500)
Goodwill, net	301,300	$ 297,200
Goodwill, Acquired During Period	0
Currency fluctuations	$ 4,100

4. Intangible Assets, Goodwi40

4. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 481.9		$ 443.2
Accumulated Amortization	(291.3)		(281.6)
Net Carrying Amount	190.6		161.6
Amortization [Abstract]
Amortization expense	6.9	$ 9.4
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	85.7		84.4
Accumulated Amortization	(55.1)		(52.8)
Net Carrying Amount	30.6		31.6
Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	184		182.6
Accumulated Amortization	(140.6)		(136.9)
Net Carrying Amount	43.4		45.7
Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	126.7		125.9
Accumulated Amortization	(58.9)		(56.3)
Net Carrying Amount	67.8		69.6
Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	74.1		39
Accumulated Amortization	(31.4)		(30.6)
Net Carrying Amount	42.7		8.4
Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	3.6		3.5
Accumulated Amortization	(2.7)		(2.5)
Net Carrying Amount	0.9		1
Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	7.8		7.8
Accumulated Amortization	(2.6)		(2.5)
Net Carrying Amount	$ 5.2		$ 5.3
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	1 year		1 year
Minimum [Member] | Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	1 year		1 year
Minimum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	2 years		3 years
Minimum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	1 year		1 year
Minimum [Member] | Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	4 years		4 years
Minimum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	2 years		2 years
Minimum [Member] | Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	0 years		0 years
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	8 years		8 years
Maximum [Member] | Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	9 years		9 years
Maximum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	12 years		12 years
Maximum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	14 years		9 years
Maximum [Member] | Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	8 years		8 years
Maximum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	7 years		9 years
Maximum [Member] | Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	0 years		0 years
Analytical Flow Cytometer Platform [Member] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired		29.7
Analytical Flow Cytometer Platform [Member] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired		$ 3

5. Product Warranty Liabilit41

5. Product Warranty Liability (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
Accrual at beginning of period	$ 17.6
Provision for warranty	8
Actual warranty costs	(8)
Accrual at end of period	$ 17.6

6. Long-Term Debt (Details)

6. Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2010
Debt Instrument [Line Items]
Debt and Capital Lease Obligations	$ 434,800	$ 434,500
Less Current Maturities	(500)	(300)
Long-term debt, net of current maturities	434,289	434,186
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]
Debt Instrument [Line Items]
Unsecured Debt	425,000	425,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 2,400	2,500
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Debt Instrument, Redemption Price, Percentage	100.00%
Long-term debt	$ 422,600	422,500	$ 422,600
Debt Instrument, Interest Rate, Effective Percentage			4.946%
Face amount of debt sold			$ 425,000
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Including Current Maturities	12,200	$ 12,000
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	200,000
Outstanding borrowings	$ 0
Line of Credit Facility, Interest Rate at Period End	2.40%
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 800

7. Accumulated Other Compreh43

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Selling, general and administrative expense	$ (194,940)	$ (189,716)
Other (income) expense, net	(1,418)	(1,177)
Accumulated other comprehensive income	516,643		$ 417,766
Total other comprehensive income (loss) net of tax	98,877	33,202
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	20,100	71,600	1,300	$ 33,700
Other Comprehensive Income (Loss), before Reclassifications, before Tax	18,800	37,900
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	0	0
Other Comprehensive Income (Loss), Tax	0	0
Total other comprehensive income (loss) net of tax	18,800	37,900
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	(18,700)	(21,300)	(18,600)	(20,700)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(300)	(900)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	200	300
Other Comprehensive Income (Loss), Tax	0	0
Total other comprehensive income (loss) net of tax	(100)	(600)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Selling, general and administrative expense	(200)	(300)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	515,200	365,000	435,000	369,100
Other Comprehensive Income (Loss), before Reclassifications, before Tax	127,100	(6,500)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(200)	0
Other Comprehensive Income (Loss), Tax	(46,700)	2,400
Total other comprehensive income (loss) net of tax	80,200	(4,100)
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	(200)	0
Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	516,600	415,300	$ 417,700	$ 382,100
Other Comprehensive Income (Loss), before Reclassifications, before Tax	145,600	30,500
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	0	300
Other Comprehensive Income (Loss), Tax	(46,700)	2,400
Total other comprehensive income (loss) net of tax	$ 98,900	$ 33,200

8. Earnings Per Share (Details

8. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Basic weighted average shares outstanding	29,580	29,364
Effect of potentially dilutive stock options and restricted stock awards	331	142
Diluted weighted average common shares	29,911	29,506
Anti-dilutive shares	17	90

9. Other Income and Expenses45

9. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Interest and investment income	$ (1,100)	$ (1,200)
Net realized gain on investments	(300)	0
Other (income) expense, net	$ (1,418)	$ (1,177)

10. Income Taxes (Details)

10. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Effective tax rate	38.00%	39.00%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 3.5
U.S. Federal [Member]
Statutory Rates	35.00%	35.00%

11. Segment Information (Detai

11. Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Net sales	$ 500,051	$ 471,197
Income before income taxes	20,147	20,195
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	174,300	165,900
Income before income taxes	(18,800)	(3,300)
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	322,300	301,700
Income before income taxes	41,000	24,800
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	3,500	3,600
Income before income taxes	$ 200	$ 300

11. Segment Profit Reconciliat

11. Segment Profit Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 20,147	$ 20,195
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	22,400	21,800
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(1,900)	(1,700)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(1,800)	(1,100)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 1,400	$ 1,200

12. Legal Proceedings 12. Cont

12. Legal Proceedings 12. Contingent Liability (Details)	3 Months Ended
	Mar. 31, 2017USD ($)
12. Legal Proceedings [Abstract]
Loss Contingency, Damages Awarded, Value	$ 10,920,000
Litigation Settlement Interest	$ 141,608

13. Restructuring Costs (Detail

13. Restructuring Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 8.2	$ 9
Restructuring Reserve, Current	5.8
Restructuring Reserve, Noncurrent	2.4
Restructuring Reserve, Accrual Adjustment	0.1
Payments for Restructuring	(0.9)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	0.1
Cost of Goods, Total [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.1)
Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	0.1
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	0
Restructuring Reserve, Accrual Adjustment	0
Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2.9	3.2
Restructuring Charges	0
Restructuring Reserve, Accrual Adjustment	0
Payments for Restructuring	(0.3)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	0
Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	5.3	$ 5.8
Restructuring Charges	0
Restructuring Reserve, Accrual Adjustment	0
Payments for Restructuring	(0.6)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	$ 0.1